Assertio

$3.80 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Assertio

Assertio Holdings, Inc. is a specialty pharmaceutical company. The Company owns a portfolio of prescription neurology, inflammation and pain medications. Its marketed products include Cambia (diclofenac potassium) for Oral solution, INDOCIN Oral Suspension, INDOCIN (indomethacin) Suppositories, OXAYDO tablets, SPRIX Nasal Spray, VIVLODEX capsules, ZIPSOR Liquid filled capsules and ZORVOLEX capsules. The Company is also focused on developing and commercializing neurology, orphan and specialty medicines. Its pipeline products include Diclofenac Potassium, Long-acting Cosyntropin and Diclofenac potassium. Diclofenac Potassium is being developed for mild/moderate acute pain. Long-acting Cosyntropin is being developed for diagnosis of adrenal insufficiency. Diclofenac potassium is a liquid formulation being developed for acute migraine attacks.

Stock Analysis

last close $3.8
1-mo return 17.3%
3-mo return 67.4%
avg daily vol. 1.32M
52-week high 4.44
52-week low 0.85
market cap. $181M
forward pe 12.5
annual div. -
roe 3%
ltg forecast -
dividend yield -
annual rev. $121M
inst own. 22.7%
baraka

Subscribe now for daily local and international financial news

Subscribe